To explore the relationship between Lp(a) and clinical outcomes of statin therapy in diabetic patients after PCI.

A retrospective analysis of 316 patients diagnosed with coronary heart disease from January 2015 to December 2018 in our hospital was divided into high Lp(a) group and low Lp(a) group according to the Lp(a) level of the included cases. Blood pressure, glycated hemoglobin (HbA1c), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), hypersensitive C-reactive protein (HsCRP), N-termina pro-brain natriuretic pep- tide(NT-proBNP), left ventricular ejection fraction (LVEF) levels were compared between the two groups, and medications were used to analyze the occurrence of major adverse cardiac events (MACE) during follow-up in both groups.

There was no statistically significant difference in systolic blood pressure, diastolic blood pressure, HbA1c, TG, HDL-C, hsCRP, NT-proBNP, LVEF between the two groups (P>0.05), while the LDL-C level in the high Lp(a) group was significantly higher In the low Lp(a) group, the difference was statistically significant (P<0.001); the proportion of patients with aspirin, beta-blocker, CCB, ACEI/ARB medications in the two groups had no statistically significant differences in proportions (P>0.05). The incidence of MACE in the high Lp(a) group was significantly higher than that in the low Lp(a) group, and the difference was statistically significant (HR: 2.07, 95% CI: 1.281-3.542, P= 0.0057).

Serum high Lp(a) levels in diabetic patients receiving statin therapy after PCI are independent risk factors for adverse cardiac events.